Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway

Open access
Wei, Jun, Barr, Jason, Kong, Ling-Yuan, Wang, Yongtao, Wu, Adam, Sharma, Amit K., Gumin, Joy, Henry, Verlene, Colman, Howard, Priebe, Waldemar, Sawaya, Raymond, Lang, Frederick F., Heimberger, Amy B. · 2010 · Molecular Cancer Therapeutics

Abstract

Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer-initiating cells have been shown to recapitulate the characteristic features of GBM and mediate chemotherapy and radiation resistance. However, it is unknown whether the cancer-initiating cells contribute to the profound immune suppression in GBM patients. Recent studies have found that the activated form of signal transducer and activator of transcription 3 (STAT3) is a key mediator in GBM immunosuppression. We isolated and generated CD133+ cancer-initiating single colonies from GBM patients and investigated their immune-suppressive properties. We found that the cancer-initiating cells inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis. The STAT3 pathway is constitutively active in these clones and the immunosuppressive properties were markedly diminished when the STAT3 pathway was blocked in the cancer-initiating cells. These findings indicate that cancer-initiating cells contribute to the immune evasion of GBM and that blockade of the STAT3 pathway has therapeutic potential. Mol Cancer Ther; 9(1); 67–78

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-0734

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 282

Metadata

Authors
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Priebe, W., Sawaya, R., Lang, F. F., & Heimberger, A. B.
Venue
Molecular Cancer Therapeutics
Published
2010-01-01
Volume
9
Issue
1
Pages
67-78
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2148131374
Cited by
282
References
61
FWCI
8.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0734
The paper
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Priebe, W., Sawaya, R., Lang, F. F., & Heimberger, A. B. (2010). Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0734

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.